21 / 24
Page 63
Journal of Pharmaceutical care and Health Systems | ISSN: 2376-0419 | Volume 5
Pharmaceutical sciences
11
th
World Congress on
September 28-29, 2018 | Montreal, Canada
Factors affecting adherence to Antihypertensive medication regimen among hemodialysis patients
attending a private hospital in Mombasa
S Otenyo
Egerton University, Kenya
Introduction:
Patients with chronic kidney disease undergoing hemodialysis are usually co-morbid with hypertension that
contributes to increased cardiovascular morbidity and mortality if not controlled. A number of factors targeted as influencing agents
to uncontrolled hypertension but adherence to treatment is counted as a major factor contributing to poor control of hypertension.
Methodology:
A cross-sectional study conducted a renal unit of a private hospital in Kenya amongst a sample size of 144 hypertensive
patients aged 18 years and above, respondents were identified using simple random sampling. Data was collected using a semi-
structured questionnaire. Data analysis using Chi-square test was applied to establish significant relationships between the dependent
variable (adherence) and independent variables (knowledge and perception), logistic regression was used to predict independent
variables that influence adherence, and results with p values ≤ 0.05 were considered statistically significant. Results: Factors that
influenced adherence to antihypertensive medication were; age p=0.23 (OR=1.02, CI=0.98-1.07), female gender had better adherence
than males P= 0.98 (OR=2.58, CI=1.09-6.16), patients with health insurance p=0.92 (OR=0.35, CI=0.15-0.84), knowledge of side
effects of medication p=0.58 (OR=2.02, CI=0.44-9.27), perception of severity P=0.69 (OR=3.61, CI=1.02-12.78), perception of benefit
p=0.30 (OR=3.22,CI=1.06-9.79), and perception of barriers p=0.75 (OR=0.23, CI=0.08-0.64).
Conclusion:
Healthcare workers should formulate interventions tailors towards scaling up adherence in those subgroups of
hypertensive patients mentioned above in order to avert morbidities and mortalities as informed by the study.
J Pharma Care Health Sys 2018, Volume 5
DOI: 10.4172/2376-0419-C3-033